GSK/Valeant's epilepsy candidate retigabine shows potential in Phase III
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline/Valeant's first-in-class potassium channel opener, retigabine, has demonstrated a significant reduction in seizure frequency in adults with inadequately controlled partial-onset epilepsy in a Phase III study, RESTORE II, presented at the American Epilepsy Society meeting in Seattle, US.